Takeshi Kumada

List of Publications by Year
in descending order

157	7,051	94269 37	66788 78
papers	citations	h-index	g-index

157	157	157	5626
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The prognosis of elderly patients with hepatocellular carcinoma: A multiâ€center 19â€year experience in Japan. Cancer Medicine, 2023, 12, 345-357.	1.3	5
2	Does firstâ€line treatment have prognostic impact for unresectable <scp>HCC</scp>?â€”Atezolizumab plus bevacizumab versus lenvatinib. Cancer Medicine, 2023, 12, 325-334.	1.3	25
3	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. Cancer Reports, 2022, 5, e1464.	0.6	43
4	Longâ€term persistence of hepatocarcinogenic potential of a nonâ€hypervascular hypointense nodule on EOBâ€MRI after the eradication of hepatitis C virus. Hepatology Research, 2022, 52, 128-132.	1.8	0
5	Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population. Hepatology Research, 2022, 52, 81-92.	1.8	11
6	Utility of Ultrasound-Guided Attenuation Parameter for Grading Steatosis With Reference to MRI-PDFF in a Large Cohort. Clinical Gastroenterology and Hepatology, 2022, 20, 2533-2541.e7.	2.4	24
7	Timeâ€course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. Hepatology Research, 2022, 52, 235-246.	1.8	7
8	Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era. Oncology, 2022, 100, 65-73.	0.9	3
9	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Hepatology Research, 2022, 52, 462-470.	1.8	18
10	HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A metaâ€analysis. Hepatology, 2022, 76, 139-154.	3.6	42
11	Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection. European Radiology, 2022, , 1.	2.3	0
12	Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response. European Journal of Gastroenterology and Hepatology, 2022, 34, 693-697.	0.8	4
13	Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma. Liver Cancer, 2022, 11, 290-314.	4.2	30
14	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLCâ€B stage patients classified as beyond up to seven criteria â€“ Multicenter analysis. Hepatology Research, 2022, 52, 308-316.	1.8	25
15	Clinical Profiles of Asians with NAFLD: A Systematic Review and Meta-Analysis. Digestive Diseases, 2022, 40, 734-744.	0.8	10
16	Liver biopsy implementation rate for diagnosis of NASH in Japan -analysis of big data of health insurance claims-. Acta Hepatologica Japonica, 2022, 63, 211-213.	0.0	0
17	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Medicine, 2022, 11, 3796-3808.	1.3	21
18	Liver Stiffness Measurements by 2D Shear-Wave Elastography: Effect of Steatosis on Fibrosis Evaluation. American Journal of Roentgenology, 2022, , .	1.0	2

#	Article	IF	Citations
19	Misunderstanding of hepatitis C virus (HCV) infection status by nonâ€“specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy. Journal of Infection and Chemotherapy, 2022, 28, 1231-1234.	0.8	2
20	Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups. BMC Gastroenterology, 2022, 22, 241.	0.8	13
21	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Scientific Reports, 2022, 12, 8421.	1.6	4
22	Intra-individual Comparisons of the Ultrasound-Guided Attenuation Parameter and the Magnetic Resonance Imagingâ€“Based Proton Density Fat Fraction Using Bias and Precision Statistics. Ultrasound in Medicine and Biology, 2022, 48, 1537-1546.	0.7	2
23	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Childâ€Pugh class A or B liver function in realâ€world clinical practice. Hepatology Research, 2022, 52, 773-783.	1.8	34
24	Ultrasound diagnosis of fatty liver disease. Choonpa Igaku, 2022, , .	0.0	0
25	Improved survival of viral <scp>hepatocellular carcinoma</scp> but not nonâ€viral <scp>hepatocellular carcinoma</scp> from 2000 to 2020: A multiâ€centre cohort study of 6007 patients from highâ€volume academic centres in Japan. Alimentary Pharmacology and Therapeutics, 2022, 56, 694-701.	1.9	9
26	Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received directâ€acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance. JGH Open, 2022, 6, 462-469.	0.7	2
27	Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albuminâ€“bilirubin score (ALBS grade). Journal of Gastroenterology, 2022, 57, 581-586.	2.3	6
28	Combined ultrasound and magnetic resonance elastography predict hepatocellular carcinoma after hepatitis C virus eradication. Hepatology Research, 2022, 52, 957-967.	1.8	2
29	Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study. Liver Cancer, 2022, 11, 527-539.	4.2	16
30	Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify. British Journal of Cancer, 2022, 127, 1263-1269.	2.9	11
31	Factors linked to hepatocellular carcinoma development beyond 10â€‰years after viral eradication in patients with hepatitis C virus. Journal of Viral Hepatitis, 2022, 29, 919-929.	1.0	5
32	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1812-1819.	1.4	28
33	Serum Levels of Î±-Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2021, 19, 162-170.e4.	2.4	24
34	Impact of directâ€acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2021, 28, 168-176.	1.0	7
35	Serial changes in FIBâ€4 score and hepatocarcinogenesis in hepatitis B patients treated with or without nucleot(s)ide analogue therapy. GastroHep, 2021, 3, 37-49.	0.3	1
36	Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. Hepatology Research, 2021, 51, 201-215.	1.8	22

#	Article	IF	Citations
37	Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis. Journal of Viral Hepatitis, 2021, 28, 538-547.	1.0	3
38	Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study. Infectious Diseases and Therapy, 2021, 10, 269-280.	1.8	0
39	Longâ€term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virusâ€"related decompensated cirrhosis. Journal of Viral Hepatitis, 2021, 28, 508-516.	1.0	7
40	Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. Gastroenterology Report, 2021, 9, 133-138.	0.6	21
41	Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis. Oncology, 2021, 99, 518-527.	0.9	5
42	Diagnosis of liver fibrosis based on quantification of factors associated with shear wave speed. Choonpa Igaku, 2021, 48, 193-199.	0.0	0
43	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. Liver Cancer, 2021, 10, 115-125.	4.2	12
44	Lenvatinib versus sorafenib in firstâ€line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. Liver International, 2021, 41, 1389-1397.	1.9	45
45	Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison. Targeted Oncology, 2021, 16, 249-254.	1.7	18
46	Abnormal fucosylation of alphaâ€fetoprotein in patients with nonalcoholic steatohepatitis. Hepatology Research, 2021, 51, 548-553.	1.8	2
47	A New Ultrasonographic â€œFluttering Signâ€•for Hepatic Hemangioma. Ultrasound in Medicine and Biology, 2021, 47, 941-946.	0.7	3
48	Reply to: â€˜Longâ€term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virusâ€•related decompensated cirrhosisâ€™. Journal of Viral Hepatitis, 2021, 28, 1099-1100.	1.0	2
49	Pretreatment nonâ€hypervascular hypointense nodules on Gdâ€EOBâ€DTPAâ€enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection. Alimentary Pharmacology and Therapeutics, 2021, 53, 1309-1316.	1.9	7
50	Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of HepatitisÂC Virus. Infectious Diseases and Therapy, 2021, 10, 1001-1013.	1.8	7
51	Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	0.8	5
52	Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus. Clinical and Translational Gastroenterology, 2021, 12, e00337.	1.3	18
53	Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response. Hepatology Communications, 2021, 5, 1290-1299.	2.0	12
54	Therapeutic efficacy of lenvatinib as thirdâ€line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatology Research, 2021, 51, 880-889.	1.8	15

#	Article	IF	Citations
55	Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitisÂC virus infection who received directâ€acting antiviral therapy and achieved sustained virological response. Hepatology Research, 2021, 51, 860-869.	1.8	8
56	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver International, 2021, 41, 2997-3008.	1.9	18
57	Longâ€term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis. Journal of Viral Hepatitis, 2021, 28, 1293-1303.	1.0	1
58	Impact of modified albuminâ€“bilirubin grade on survival in patients with HCC who received lenvatinib. Scientific Reports, 2021, 11, 14474.	1.6	13
59	Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2021, 33, 1451-1458.	0.8	10
60	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Scientific Reports, 2021, 11, 16663.	1.6	30
61	Lack of hepatitis C virus reinfection in lifetime of Japanese general population with previous hepatitis C virus (HCV) infection successfully treated with anti-HCV therapy. Journal of Infection and Chemotherapy, 2021, 27, 1674-1675.	0.8	7
62	Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels. European Journal of Gastroenterology and Hepatology, 2021, 32, 255-260.	0.8	10
63	Plateletâ€“lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. European Journal of Gastroenterology and Hepatology, 2021, 32, 261-268.	0.8	9
64	Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B. European Journal of Gastroenterology and Hepatology, 2021, 33, e898-e904.	0.8	3
65	Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response. Clinical Infectious Diseases, 2020, 70, 1208-1214.	2.9	20
66	Liver stiffness does not affect ultrasoundâ€guided attenuation coefficient measurement in the evaluation of hepatic steatosis. Hepatology Research, 2020, 50, 190-198.	1.8	35
67	GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2020, 18, 728-735.e4.	2.4	167
68	Realâ€world experience of 12â€week directâ€acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 855-861.	1.4	23
69	Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer, 2020, 9, 73-83.	4.2	37
70	Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching. Hepatology Research, 2020, 50, 75-83.	1.8	44
71	Editorial: the emergence of nonâ€hypervascular hypointense nodules in Gdâ€EOBâ€DTPAâ€enhanced MRI in patients with chronic hepatitis C. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 169-170.	1.9	0
72	Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1229-1237.	1.4	13

#	Article	IF	Citations
73	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology, 2020, 73, 1368-1378.	1.8	158
74	Impact of the introduction of directâ€acting antiâ€viral drugs on hepatocarcinogenesis: a prospective serial followâ€up MRI study. Alimentary Pharmacology and Therapeutics, 2020, 52, 359-370.	1.9	9
75	Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics, 2020, 10, 579.	1.3	21
76	Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma. Applied Sciences (Switzerland), 2020, 10, 7178.	1.3	2
77	PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication. Journal of Gastroenterology, 2020, 55, 1162-1170.	2.3	9
78	The albuminâ€“bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC. Scientific Reports, 2020, 10, 17812.	1.6	10
79	Impact of COVIDâ€19 pandemic on surveillance of hepatocellular carcinoma: A study in patients with chronic hepatitis C after sustained virologic response. GastroHep, 2020, 2, 247-252.	0.3	10
80	Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: A comparison with magnetic resonance imagingâ€determined proton density fat fraction. Hepatology Research, 2020, 50, 1319-1327.	1.8	29
81	Editorial: impact of the introduction of directâ€acting antiviral drugs on hepatocarcinogenesisâ€”a prospective serial followâ€up MRI study. Authorâ€™s reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 737-738.	1.9	0
82	Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. Infectious Diseases and Therapy, 2020, 9, 851-866.	1.8	16
83	Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. Liver Cancer, 2020, 9, 518-528.	4.2	22
84	Longâ€term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model. Hepatology Research, 2020, 50, 936-946.	1.8	5
85	The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatology International, 2020, 14, 225-238.	1.9	25
86	Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. Oncology, 2020, 98, 295-302.	0.9	24
87	Neutrophilâ€toâ€lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Liver International, 2020, 40, 968-976.	1.9	51
88	Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. Cancers, 2020, 12, 293.	1.7	34
89	Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a realâ€world setting: A large, multicenter study from Japan. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1420-1425.	1.4	3
90	Use of hepatitis B virus coreâ€related antigen to evaluate natural history of chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 2202-2209.	1.4	8

#	Article	IF	Citations
91	EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. Liver Cancer, 2020, 9, 734-743.	4.2	35
92	Relationship between COVID-19 and liver diseases: the role of hepatologists in clinical practice. Acta Hepatologica Japonica, 2020, 61, 496-503.	0.0	2
93	Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer, 2019, 8, 121-129.	4.2	159
94	Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis. Hepatology Research, 2019, 49, 111-117.	1.8	81
95	Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 436-441.	1.4	21
96	Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. Oncology, 2019, 97, 277-285.	0.9	66
97	Natural history of liverâ€related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model. Journal of Medical Virology, 2019, 91, 1837-1844.	2.5	12
98	Usefulness of Attenuation Imaging with an Ultrasound Scanner for the Evaluation of Hepatic Steatosis. Ultrasound in Medicine and Biology, 2019, 45, 2679-2687.	0.7	102
99	The emergence of nonâ€hypervascular hypointense nodules on Gdâ€EOBâ€DTPAâ€enhanced MRI in patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2019, 50, 1232-1238.	1.9	7
100	Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma. Oncology, 2019, 97, 334-340.	0.9	39
101	Trends and Efficacy of Interferon-Free Antiâ€“hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan. Open Forum Infectious Diseases, 2019, 6, ofz185.	0.4	18
102	Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in realâ€world conditionsâ€”Multicenter analysis. Cancer Medicine, 2019, 8, 3719-3728.	1.3	131
103	The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma. Journal of Gastroenterology, 2019, 54, 829-836.	2.3	6
104	Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middleâ€aged patients with nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 2011-2018.	1.4	41
105	Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. Liver Cancer, 2019, 8, 403-411.	4.2	28
106	The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Alimentary Pharmacology and Therapeutics, 2019, 49, 1230-1241.	1.9	41
107	Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma. Cancers, 2019, 11, 203.	1.7	6
108	Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer, 2019, 8, 312-325.	4.2	88

#	Article	IF	Citations
109	Clinical features of lenvatinib for unresectable hepatocellular carcinoma in realâ€world conditions: Multicenter analysis. Cancer Medicine, 2019, 8, 137-146.	1.3	112
110	Impact of albuminâ€“bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using timeâ€dependent receiver operating characteristic. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1066-1073.	1.4	40
111	Utility of Attenuation Coefficient Measurement Using an Ultrasound-Guided Attenuation Parameter for Evaluation of Hepatic Steatosis: Comparison With MRI-Determined Proton Density Fat Fraction. American Journal of Roentgenology, 2019, 212, 332-341.	1.0	70
112	Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and allâ€oral direct acting antivirals in patients with chronic hepatitis C virus infection. Hepatology Research, 2019, 49, 512-520.	1.8	2
113	Efficacy of directâ€acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study. Hepatology Research, 2019, 49, 125-135.	1.8	15
114	The impact of HCV eradication by directâ€acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study. Liver International, 2019, 39, 448-454.	1.9	26
115	Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model. European Journal of Gastroenterology and Hepatology, 2019, 31, 1452-1459.	0.8	3
116	A case of intraductal papillary neoplasm of the bile duct observed by follow-up ultrasonic examination. Choonpa Igaku, 2019, 46, 443-452.	0.0	0
117	Long-term natural history of liver disease in patients with chronic hepatitis B virus infection: an analysis using the Markov chain model. Journal of Gastroenterology, 2018, 53, 1196-1205.	2.3	22
118	Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease. Hepatology Research, 2018, 48, 549-555.	1.8	19
119	A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin-bilirubin grade. Hepatology Research, 2018, 48, E61-E67.	1.8	19
120	Hepatitis B virus coreâ€related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 918-925.	1.4	29
121	Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with nonâ€interferonâ€based treatments. Alimentary Pharmacology and Therapeutics, 2018, 48, 664-670.	1.9	20
122	Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy. Journal of Viral Hepatitis, 2018, 25, 1446-1451.	1.0	16
123	Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. Journal of Gastroenterology, 2018, 53, 1276-1284.	2.3	25
124	Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. British Journal of Cancer, 2017, 116, 441-447.	2.9	46
125	Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis <scp>C</scp> virus genotype 1b infection: Realâ€world data. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1879-1886.	1.4	10
126	Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer, 2017, 6, 204-215.	4.2	159

#	Article	IF	Citations
127	Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B. Journal of Hepatology, 2017, 66, 521-527.	1.8	41
128	Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. Digestive Diseases, 2017, 35, 602-610.	0.8	113
129	Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer, 2017, 6, 325-336.	4.2	202
130	Viral eradication reduces allâ€cause mortality, including nonâ€“liverâ€related disease, in patients with progressive hepatitis C virusâ€related fibrosis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 687-694.	1.4	23
131	Postâ€treatment levels of Î±â€fetoprotein predict longâ€term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C. Hepatology Research, 2017, 47, 1021-1031.	1.8	22
132	Progression of liver fibrosis is associated with nonâ€liverâ€related mortality in patients with nonalcoholic fatty liver disease. Hepatology Communications, 2017, 1, 899-910.	2.0	38
133	Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFNâ€free therapy for HCV. Hepatology, 2016, 64, 1818-1819.	3.6	32
134	Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade. Oncology, 2016, 91, 153-161.	0.9	36
135	Viral eradication reduces allâ€cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver International, 2016, 36, 817-826.	1.9	57
136	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. British Journal of Cancer, 2016, 114, 744-750.	2.9	150
137	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. Clinical Gastroenterology and Hepatology, 2016, 14, 875-886.e6.	2.4	217
138	HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. Journal of Hepatology, 2016, 65, 48-56.	1.8	125
139	Usefulness of albuminâ€“bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1031-1036.	1.4	198
140	Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approachâ€”The ALBI Grade. Journal of Clinical Oncology, 2015, 33, 550-558.	0.8	1,810
141	Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. Liver Cancer, 2015, 4, 126-136.	4.2	125
142	Postinterferon Î±-fetoprotein elevation and risk of hepatocellular carcinoma development after sustained virological response: Cause or results?. Hepatology, 2014, 60, 762-763.	3.6	3
143	Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. Journal of Gastroenterology, 2014, 49, 1485-1494.	2.3	7
144	High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. Journal of Gastroenterology, 2014, 49, 555-563.	2.3	57

#	Article	IF	Citations
145	Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: A multicenter study. Journal of Medical Virology, 2013, 85, 65-70.	2.5	4
146	Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: A propensity score analysis. Journal of Hepatology, 2013, 58, 427-433.	1.8	124
147	Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy. Journal of Hepatology, 2013, 58, 1174-1180.	1.8	66
148	Characteristics of elderly hepatitis <scp>C</scp> virusâ€associated hepatocellular carcinoma patients. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 357-364.	1.4	11
149	Extended treatment duration overcomes the requirement for profound week-4 interferon responsiveness in order for hepatitis C genotype 1 patients with unfavorable IL-28B genotype to achieve sustained virologic response. Journal of Clinical Virology, 2013, 57, 381.	1.6	0
150	High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4Âweeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b. Journal of Gastroenterology, 2011, 46, 501-509.	2.3	10
151	Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. Journal of Gastroenterology, 2011, 46, 536-544.	2.3	40
152	Evolution of Hypointense Hepatocellular Nodules Observed Only in the Hepatobiliary Phase of Gadoxetate Disodiumâ€"Enhanced MRI. American Journal of Roentgenology, 2011, 197, 58-63.	1.0	141
153	Efficacy of peginterferon-Î±-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver International, 2010, 30, 527-537.	1.9	58
154	Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. Journal of Hepatology, 2009, 50, 729-735.	1.8	45
155	Impact of Surveillance on Survival of Patients With Initial Hepatocellular Carcinoma: A Study From Japan. Clinical Gastroenterology and Hepatology, 2006, 4, 1170-1176.	2.4	57
156	Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver International, 2005, 25, 848-853.	1.9	63
157	Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. Journal of Hepatology, 1999, 30, 125-130.	1.8	136